AstraZeneca Licenses Protherics Sepsis Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.
You may also be interested in...
No AstraZeneca Cash Takeover; BTG Offers Protherics Stock Deal Instead
Merger valued at $396 million-plus, but widely speculated sepsis partner not the one.
No AstraZeneca Cash Takeover; BTG Offers Protherics Stock Deal Instead
Merger valued at $396 million-plus, but widely speculated sepsis partner not the one.
Sepsis Set Back: AstraZeneca CytoFab Development Will Be Delayed Two Years
The company will conduct a 21-month Phase II study prior to initiating a Phase III trial.